Physician profile
Nicholas Fox
NPI 1780178004
$4,566.31
in general payments reported to CMS, 2019-2025
29 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $985 · 2023: $1,049 · 2024: $1,242 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.90 | 2021-2025 | |
| Novo Nordisk INC | $473.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $366.19 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.42 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $282.64 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $227.78 | 2022-2025 | |
| Glaxosmithkline, LLC. | $219.64 | 2021-2025 | Shingrix, Arexvy, Pediarix |
| Sumitomo Pharma America, INC. | $210.02 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $197.18 | 2021-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Pfizer INC. | $136.92 | 2023-2025 | |
| Astellas Pharma US INC | $132.71 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $132.09 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $116.00 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $100.06 | 2021-2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $97.47 | 2022-2025 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $91.05 | 2023-2025 | Auvelity, Symbravo |
| Sanofi-Aventis U.S. LLC | $82.09 | 2021-2023 | |
| Abbott Laboratories | $61.54 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.22 | 2022-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $45.34 | 2024 | Voquezna |
| Dexcom, INC. | $44.02 | 2022-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $41.17 | 2024-2025 | Rexulti |
| Sanofi Pasteur INC. | $37.09 | 2022-2025 | |
| Amarin Pharma, INC. | $34.01 | 2022 | |
| Amgen INC. | $33.48 | 2022-2023 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.85 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $16.73 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Tris Pharma INC | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.